US FDA warns Novo for second time about misleading Ozempic advertising

US FDA warns Novo for second time about misleading drug advertising | ReutersSkip to main content[Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv]A box of Ozempic and contents sit on a table in Dudley, North Tyneside, Britain, October 31, 2023. REUTERS/Lee Smith [Purchase Licensing Rights, opens new tab]- Companies[Novo Nordisk A/S]Follow[U.S. Food and Drug Administration]FollowMarch 3 (Reuters) - The U.S. Food and Drug Administration has told Novo Nordisk [(NO ...